Advertisement Advertisement July 20, 2022 July 20, 2022—Robocath, a developer of robotic platforms for the treatment of vascular diseases based in Rouen, France, announced that its joint venture, Cathbot, has enrolled the last patient in its clinical study in China. Robocath established Cathbot in 2020 with Shanghai, China-based MicroPort through its robotic subsidiary MedBot. According to the company, this is the first step towards obtaining approval from China’s National Medical Products Administration for the commercialization of its R-One robotic solution for percutaneous coronary intervention (PCI) in the Chinese market, where this is the first clinical study conducted on this scale...